Myocardial Ischemia

• 

  Subject Areas on Research

  • "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship. 
  • 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. 
  • A case of severe ischemia-induced QT prolongation. 
  • A clinical investigation on tong xin luo capsule in treatment of coronary heart disease with silent myocardial ischemia. 
  • A comparison of mechanical and laser transmyocardial revascularization for induction of angiogenesis and arteriogenesis in chronically ischemic myocardium. 
  • A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 
  • A load-independent in vivo model for evaluating therapeutic interventions in injured myocardium. 
  • A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans Affairs. 
  • A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. 
  • A risk score to predict in-hospital mortality for percutaneous coronary interventions. 
  • A standardized definition of ischemic cardiomyopathy for use in clinical research. 
  • A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. 
  • A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. 
  • A theoretical analysis of acute ischemia and infarction using ECG reconstruction on a 2-D model of myocardium. 
  • A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. 
  • ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. 
  • ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 
  • ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. 
  • ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. 
  • ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. 
  • ACI-TIPI clinical trial. Acute cardiac ischemia time-insensitive predictive instrument. 
  • ACR Appropriateness Criteria® Dyspnea-Suspected Cardiac Origin. 
  • AHA scientific statement: practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized electrocardiology and the American Association of Critical-Care Nurses. 
  • Abnormalities of retinal microvascular structure and risk of mortality from ischemic heart disease and stroke. 
  • Acute ischemic heart disease. 
  • Acute ischemic syndromes. 
  • Adaptive mechanisms that preserve cardiac function in mice without myoglobin. 
  • Addition of right-sided and posterior precordial leads during stress testing. 
  • Adenosine A3 receptor stimulation attenuates postischemic dysfunction through KATP channels 
  • Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. 
  • Adenosine-induced flow arrest to facilitate intracranial aneurysm clip ligation does not worsen neurologic outcome. 
  • Adhesion molecules, platelet activation, and cardiovascular risk. 
  • Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators. 
  • Alcohol and the Heart: A Proteomics Analysis of Pericardium and Myocardium in a Swine Model of Myocardial Ischemia. 
  • Alcohol consumption improves insulin signaling in the myocardium. 
  • Alcohol consumption mitigates apoptosis and mammalian target of rapamycin signaling in myocardium. 
  • An in vitro system to evaluate the effects of ischemia on survival of cells used for cell therapy. 
  • An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group. 
  • An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). 
  • An overview of the results of the EPIC trial. 
  • Anaphylaxis and coronary disease [4] 
  • Anger and mental stress-induced myocardial ischemia: mechanisms and clinical implications. 
  • Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. 
  • Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization. 
  • Anomalous aortic origin of a coronary artery: a report from the Congenital Heart Surgeons Society Registry. 
  • Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. 
  • Anticoagulant therapy for percutaneous coronary intervention. 
  • Antidepressant therapy in patients with ischemic heart disease. 
  • Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. 
  • Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. 
  • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. 
  • Appropriateness of percutaneous coronary intervention. 
  • Aspirin and clopidogrel resistance: consideration and management. 
  • Assessing risk for coronary heart disease: beyond Framingham. 
  • Assessment of Diastolic Function Using Ultrasound Elastography. 
  • Assessment of derived 12-lead electrocardiograms using general and patient-specific reconstruction strategies at rest and during transient myocardial ischemia. 
  • Assessment of myocardial viability by cardiovascular magnetic resonance imaging. 
  • Assessment of no-reflow regions using cardiac MRI. 
  • Assessment of regional wall motion abnormalities with real-time 3-dimensional echocardiography. 
  • Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y12 Inhibitors in Patients With Acute Coronary Syndrome. 
  • Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation 
  • Association between physician billing and cardiac stress testing patterns following coronary revascularization. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Association of physical fitness and transient myocardial ischemia in patients with coronary artery disease. 
  • Association of systolic blood pressure at time of myocardial ischemia with angina pectoris during exercise testing. 
  • Associations between positive emotional well-being and stress-induced myocardial ischemia: Well-being scores predict exercise-induced ischemia. 
  • Asymmetric versus symmetric tethering patterns in ischemic mitral regurgitation: geometric differences from three-dimensional transesophageal echocardiography. 
  • Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial. 
  • Atorvastatin regulates apoptosis in chronically ischemic myocardium. 
  • Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. 
  • Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. 
  • Biomarkers: Troponin testing—risk stratification to stratified medicine 
  • Bivalirudin for patients with acute coronary syndromes. 
  • Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. 
  • Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients. 
  • Blood transfusion in patients with acute coronary syndrome. 
  • CMR First-Pass Perfusion for Suspected Inducible Myocardial Ischemia. 
  • Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. 
  • Calpain inhibition decreases myocardial apoptosis in a swine model of chronic myocardial ischemia. 
  • Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia. 
  • Cardiac MR for the assessment of myocardial viability. 
  • Cardiac Troponin and Risk Stratification in Ischemic Heart Disease. 
  • Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. 
  • Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. 
  • Cardiac troponins in congestive heart failure. 
  • Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. 
  • Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. 
  • Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. 
  • Case study: heart transplantation--increased incidence of acute rejection in female recipients. 
  • Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trials. 
  • Cell therapy for heart failure: the need for a new therapeutic strategy. 
  • Changes in beliefs about medications during long-term care for ischemic heart disease. 
  • Changes in high-frequency QRS components during prolonged coronary artery occlusion in humans. 
  • Changes in plasma volume associated with mental stress ischemia in patients with coronary artery disease. 
  • Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. 
  • Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative. 
  • Chronic ischemic heart disease. 
  • Clinical applications of coronary sinus retroperfusion during high risk percutaneous transluminal coronary angioplasty. 
  • Clinical applications of highly sensitive troponin assays. 
  • Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. 
  • Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. 
  • Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 
  • Clinical characteristics of patients undergoing surgical ventricular reconstruction by choice and by randomization. 
  • Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE). 
  • Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. 
  • Clinical outcomes of bivalirudin for ischemic heart disease. 
  • Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. 
  • Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. 
  • Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. 
  • Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. 
  • Coenzyme Q10 protects ischemic myocardium in an open-chest swine model. 
  • Combined TMR and mitral valve replacement via left thoracotomy. 
  • Comparability of 12-lead ECGs derived from EASI leads with standard 12-lead ECGS in the classification of acute myocardial ischemia and old myocardial infarction. 
  • Comparative Effectiveness Trials of Imaging-Guided Strategies in Stable Ischemic Heart Disease. 
  • Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. 
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. 
  • Comparison of Clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease). 
  • Comparison of an automated algorithm to expert physician interpretation of 80-lead body surface mapping in the evaluation of acute myocardial ischemia and infarction in patients presenting to the emergency department with chest pain: results from the Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction trial. 
  • Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. 
  • Comparison of electrocardiogram and intrathoracic electrogram signals for detection of ischemic ST segment changes during normal sinus and ventricular paced rhythms. 
  • Comparison of high-frequency QRS components and ST-segment elevation to detect and quantify acute myocardial ischemia. 
  • Comparison of long-term effect of coronary artery bypass grafting in patients with ischemic cardiomyopathy with viable versus nonviable left ventricular myocardium. 
  • Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. 
  • Comparison of troponin T and creatine Kinase-MB fraction in evaluating cardiac patients postoperatively. 
  • Compromised atrial coronary anatomy is associated with atrial arrhythmias and atrioventricular block complicating acute myocardial infarction. 
  • Concealed mechanical bradycardia: an indication for permanent pacemaker implantation. 
  • Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. 
  • Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. 
  • Contribution of health status and prevalent chronic disease to individual risk for workplace injury in the manufacturing environment. 
  • Contribution of the Veterans Health Administration in understanding racial disparities in access and utilization of health care: a spirit of inquiry. 
  • Controlled human exposures to ambient pollutant particles in susceptible populations. 
  • Controversies in cardiovascular MR imaging: T2-weighted imaging should not be used to delineate the area at risk in ischemic myocardial injury. 
  • Coronary artery disease epidemic in Pakistan: more electrocardiographic evidence of ischaemia in women than in men. 
  • Coronary steal from a left internal mammary artery coronary bypass graft by a left upper extremity arteriovenous hemodialysis fistula. 
  • Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. 
  • Correction of a saphenous vein graft to coronary vein anastamosis by selective retrograde coil-induced occlusion to arterialize the native vein. 
  • Cost effectiveness of abciximab during routine medical practice. 
  • Cost estimates for treatment of cardiac ischemia (from the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). 
  • Cost-effectiveness of revascularization strategies: the ASCERT study. 
  • Critical concepts in cost-effectiveness for cardiovascular specialists. 
  • Current State of Stem Cell Therapy for Ischemic Heart Disease. 
  • Current advances in the use of therapeutic hypothermia. 
  • Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. 
  • Cytokine mRNA expression in postischemic/reperfused myocardium. 
  • Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough. 
  • Degradation of spectrin and ankyrin in the ischemic rat kidney. 
  • Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. 
  • Depression and increased myocardial ischemic activity in patients with ischemic heart disease. 
  • Depression and ischemic heart disease. 
  • Depression and ischemic heart disease: overview of the evidence and treatment implications. 
  • Depression and ischemic heart disease: what have we learned from clinical trials? 
  • Depression and ischemic heart disease: what have we learned so far and what must we do in the future? 
  • Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease. 
  • Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. 
  • Detection of myocardial ischemia by stress perfusion cardiovascular magnetic resonance. 
  • Detection of silent ischemia adds to the prognostic value of coronary anatomy and left ventricular function in predicting outcome in unstable angina patients. 
  • Diabetes and ischemic heart disease. 
  • Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization. 
  • Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. 
  • Diagnostic performance of computed tomography angiography for differentiating ischemic vs nonischemic cardiomyopathy. 
  • Differences between chest pain observation service patients and admitted "rule-out myocardial infarction" patients. 
  • Differential effects of atorvastatin on autophagy in ischemic and nonischemic myocardium in Ossabaw swine with metabolic syndrome. 
  • Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. 
  • Digoxin measurements following plasma ultrafiltration in two patients with digoxin toxicity treated with specific Fab fragments. 
  • Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. 
  • Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease? 
  • Does resveratrol improve insulin signaling in chronically ischemic myocardium? 
  • Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. 
  • Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. 
  • Early-Life State-of-Residence Characteristics and Later Life Hypertension, Diabetes, and Ischemic Heart Disease. 
  • Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. 
  • Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon Pump. 
  • Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. 
  • Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). 
  • Effect of age on outcome with primary angioplasty versus thrombolysis. 
  • Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. 
  • Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. 
  • Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. 
  • Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. 
  • Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. 
  • Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. 
  • Effect of platelet inhibition with cangrelor during PCI on ischemic events. 
  • Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effects of Alcohol on Postoperative Adhesion Formation in Ischemic Myocardium and Pericardium. 
  • Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). 
  • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. 
  • Effects of daily stress on autonomic cardiac control in patients with coronary artery disease. 
  • Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. 
  • Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. 
  • Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. 
  • Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. 
  • Effects of mental stress on myocardial ischemia during daily life. 
  • Effects of peroneal nerve stimulation on hypothalamic stimulation-induced ventricular arrhythmias in rabbits. 
  • Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. 
  • Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. 
  • Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). 
  • Efficacy of zoniporide, an Na/H exchange ion inhibitor, for reducing perioperative cardiovascular events in vascular surgery patients. 
  • Efficiency comparison between 99m Tc-tetrofosmin and 99m Tc-sestamibi myocardial perfusion studies. 
  • Electrocardiographic factors playing a role in ischemic ventricular fibrillation in ST elevation myocardial infarction are related to the culprit artery. 
  • Elevation in serum troponin I predicts the benefit of tirofiban. 
  • Emotional triggering of cardiac dysfunction: the present and future. 
  • Enhanced External Counterpulsation (EECP): enough evidence to support this and the next wave? 
  • Enhancement of cardiac function by cyclocreatine in models of cardiopulmonary bypass. 
  • Enhancing standard cardiac rehabilitation with stress management training: background, methods, and design for the enhanced study. 
  • Enhancing stem cell therapy through genetic modification. 
  • Erythropoietin in cardiovascular diseases: exploring new avenues. 
  • Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. 
  • Ethanol promotes new vessel growth in remote nonischemic myocardium. 
  • Ethnic differences in the treatment of depression in patients with ischemic heart disease. 
  • Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. 
  • Evaluation of depolarization changes during acute myocardial ischemia by analysis of QRS slopes. 
  • Evaluation of novel ECG signal processing on quantification of transient ischemia and baseline wander suppression. 
  • Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction. 
  • Evolution of an automated ST-segment analysis program for dynamic real-time, noninvasive detection of coronary occlusion and reperfusion. 
  • Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). 
  • Exploring the role of pH in modulating the effects of lidocaine in virtual ischemic tissue. 
  • Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. 
  • Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. 
  • Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. 
  • Free radical scavenger specifically prevents ischemic focal ventricular tachycardia. 
  • Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. 
  • Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). 
  • Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Frontiers in cardiovascular magnetic resonance. 
  • Functional capacity in men and women following cardiac rehabilitation. 
  • GP IIb/IIIa blockade in elective percutaneous coronary intervention. 
  • Gene and cell-based therapies for heart disease. 
  • Gene therapy: role in myocardial protection. 
  • Genomics and the circulation. 
  • Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. 
  • Glutamine preserves cardiomyocyte viability and enhances recovery of contractile function after ischemia-reperfusion injury. 
  • Glycogen Synthase Kinase 3β Inhibition Improves Myocardial Angiogenesis and Perfusion in a Swine Model of Metabolic Syndrome. 
  • Grade 3 ischemia on admission electrocardiogram and chest pain duration predict failure of ST-segment resolution after primary percutaneous coronary intervention for acute myocardial infarction. 
  • Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis. 
  • Heart failure in sub-Saharan Africa. 
  • Heat shock proteins and ischemic injury to the myocardium. 
  • Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. 
  • Hiatal hernia depicted on Tc-99m sestamibi images: myocardial perfusion imaging. 
  • High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. 
  • High-dose statins in acute coronary syndromes. 
  • High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. 
  • Highlights from the 71st American Heart Association Scientific Sessions: November 8 to 11, 1998. 
  • Hostility, coronary heart disease, and ischemia. The role of socioeconomic status. 
  • How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts. 
  • How should clinicians interpret clinical trials? 
  • Human pathologic correlation with PET in ischemic and nonischemic cardiomyopathy. 
  • ISCHEMIA in chronic kidney disease: improving the representation of patients with chronic kidney disease in cardiovascular trials. 
  • Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance. 
  • Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. 
  • Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 
  • Impact of Left Ventricular to Mitral Valve Ring Mismatch on Recurrent Ischemic Mitral Regurgitation After Ring Annuloplasty. 
  • Impact of an interactive video on decision making of patients with ischemic heart disease. 
  • Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. 
  • Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Impact of infarct artery patency on the relationship between electrocardiographic and ventriculographic evidence of acute myocardial ischaemia. 
  • Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting. 
  • Impact of statin use on exercise-induced cardiac troponin elevations. 
  • Impacts of depression and emotional distress on cardiac disease. 
  • Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. 
  • Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Implications and challenges using practice guidelines for chronic angina. 
  • Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. 
  • In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
  • Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. 
  • Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review. 
  • Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. 
  • Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? 
  • Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. 
  • Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction: Results From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 
  • Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. 
  • Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. 
  • Inhibition of the cardiomyocyte-specific troponin I-interacting kinase limits oxidative stress, injury, and adverse remodeling due to ischemic heart disease. 
  • Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. 
  • Inter-regional differences in acute coronary syndrome trials. 
  • Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study. 
  • Intramyocardial, autologous CD34+ cell therapy for refractory angina. 
  • Introduction. 
  • Investigating the effects of resveratrol on chronically ischemic myocardium in a swine model of metabolic syndrome: a proteomics analysis. 
  • Invited commentary. 
  • Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. 
  • Is it time for a randomized trial of surgical treatment of ischemic heart failure? 
  • Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction. 
  • Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. 
  • Ischemic hibernating myocardium demonstrated by positron emission tomography in anomalous origin of the left coronary artery from the pulmonary artery. 
  • Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study. 
  • Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. 
  • Issues with care in the elderly patient presenting with acute ischemia. 
  • Issues with care in the elderly patient presenting with acute ischemia. 
  • IxCELL-DCM: rejuvenation for cardiac regenerative therapy? 
  • Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried? 
  • Lessons from SADHART, ENRICHD, and other trials. 
  • Lessons learned and a look to the future: the Chronic Ischemic Heart Disease (CICD) Pilot Registry 
  • Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease. 
  • Linkages between facial expressions of anger and transient myocardial ischemia in men with coronary artery disease. 
  • Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. 
  • Low hot pain threshold predicts shorter time to exercise-induced angina: results from the psychophysiological investigations of myocardial ischemia (PIMI) study. 
  • Low-dose dobutamine tissue-tagged magnetic resonance imaging with 3-dimensional strain analysis allows assessment of myocardial viability in patients with ischemic cardiomyopathy. 
  • Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. 
  • Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. 
  • MR imaging of myocardial perfusion and viability. 
  • Magnetocardiogram recordings in a nonshielded environment--reproducibility and ischemia detection. 
  • Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure: A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. 
  • Markers of cardiac ischemia and inflammation. 
  • Markers of cardiac ischemia, injury, and inflammation. 
  • Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. 
  • Mental stress and coronary disease. The Smart-Heart Study. 
  • Mental stress--induced myocardial ischemia and cardiac events. 
  • Mental stress-induced ischemia in the laboratory and ambulatory ischemia during daily life. Association and hemodynamic features. 
  • Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. 
  • Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. 
  • Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention. 
  • Metabolic syndrome impairs notch signaling and promotes apoptosis in chronically ischemic myocardium. 
  • Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. 
  • Metformin mitigates apoptosis in ischemic myocardium. 
  • MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. 
  • Microvascular disease and cardiomyopathy. 
  • Microvascular notch signaling is upregulated in response to vascular endothelial growth factor and chronic myocardial ischemia. 
  • Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine. 
  • Mitral gradients and frequency of recurrence of mitral regurgitation after ring annuloplasty for ischemic mitral regurgitation. 
  • Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. 
  • Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. 
  • Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings. 
  • Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol. 
  • Multicenter study of target-controlled infusion of propofol-sufentanil or sufentanil-midazolam for coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. 
  • Multimodal detection of perioperative myocardial ischemia. 
  • Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. 
  • Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. 
  • Myocardial ischemia correlates with reduced fibrinolytic activity following peripheral vascular surgery. 
  • Myocardial viability and survival in ischemic left ventricular dysfunction. 
  • Myonecrosis after revascularization procedures. 
  • National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. 
  • National and regional registries: what good are they? 
  • Natriuretic peptide testing in clinical medicine. 
  • Navigating the crossroads of coronary artery disease and heart failure. 
  • Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia. 
  • Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. 
  • Noninvasive, quantitative assessment of left ventricular function in ischemic cardiomyopathy. 
  • Nutritional risk and the metabolic syndrome in women: opportunities for preventive intervention from the Framingham Nutrition Study. 
  • O-linked β-N-acetylglucosamine modification of proteins is activated in post-ischemic brains of young but not aged mice: Implications for impaired functional recovery from ischemic stress. 
  • Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • Optimal non-invasive imaging test selection for the diagnosis of ischaemic heart disease. 
  • Optimal surgical management of severe ischemic mitral regurgitation: to repair or to replace? 
  • Outcomes with an alternate list strategy for heart transplantation. 
  • Overcoming the challenges facing quality-improvement strategies for non-ST-segment elevation acute coronary syndromes. 
  • Pathophysiology and time course of silent myocardial ischaemia during mental stress: clinical, anatomical, and physiological correlates. 
  • Pathophysiology of cardiac extracorporeal membrane oxygenation. 
  • Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. 
  • Patient survival characteristics after routine mitral valve repair for ischemic mitral regurgitation. 
  • Patterns of use and comparative effectiveness of bleeding avoidance strategies in men and women following percutaneous coronary interventions: an observational study from the National Cardiovascular Data Registry. 
  • Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). 
  • Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: The VA AWESOME multicenter registry: comparison with the randomized clinical trial. 
  • Performance of ST and ventricular gradient difference vectors in electrocardiographic detection of acute myocardial ischemia. 
  • Perioperative complications influence recurrence and survival after resection of hepatic colorectal metastases. 
  • Periprocedural myocardial ischemia in patients with severe symptomatic coronary artery disease undergoing endoscopy: prevalence and risk factors. 
  • Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. 
  • Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging. 
  • Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy. 
  • Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure. 
  • Platelet activation in myocardial ischemic syndromes. 
  • Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. 
  • Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology. 
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. 
  • Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. 
  • Positive predictive value of a point-of-care testing strategy on first-draw specimens for the emergency department-based detection of acute coronary syndromes. 
  • Postcoronary thrombolysis management. 
  • Postoperative inotrope and vasopressor use following CABG: outcome data from the CAPS-care study. 
  • Poststress measurements of left ventricular function with gated perfusion SPECT: comparison with resting measurements by using a same-day perfusion-function protocol. 
  • Potential of an intracardiac electrogram for the rapid detection of coronary artery occlusion. 
  • Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. 
  • Pre-hospital synthesized 12-lead ECG ischemia monitoring with trans-telephonic transmission in acute coronary syndromes: pilot study results of the ST SMART trial. 
  • Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation. 
  • Predicting survival after coronary revascularization for ischemic cardiomyopathy. 
  • Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. 
  • Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). 
  • Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. 
  • Predictors of hospital mortality in the global registry of acute coronary events. 
  • Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators. 
  • Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. 
  • Prehospitalization antiplatelet therapy and outcomes after saphenous vein graft intervention. 
  • Preoteomics, metabolomics and progenitor cells in acute coronary syndromes. 
  • Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. 
  • Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. 
  • Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. 
  • Prognostic value of PET myocardial perfusion imaging in obese patients. 
  • Prognostic value of the admission electrocardiogram in acute coronary syndromes. 
  • Programmed Outcome Research Teams (PORTs) and implications for clinical practice. 
  • Prospective, randomized trial comparing blood and oxygenated crystalloid cardioplegia in reoperative coronary artery bypass grafting. 
  • Protamine contributes to myocardial ischemia. 
  • Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome. 
  • Protective responses in the ischemic myocardium. 
  • Proteomic Profiling Reveals Adaptive Responses to Surgical Myocardial Ischemia-Reperfusion in Hibernating Arctic Ground Squirrels Compared to Rats. 
  • Psychophysical responses to a speech stressor: correlation of plasma beta-endorphin levels at rest and after psychological stress with thermally measured pain threshold in patients with coronary artery disease. 
  • Pure annular dilation as a cause of mitral regurgitation: a clinically distinct entity of female heart disease. 
  • QT prolongation and dispersion in myocardial ischemia and infarction. 
  • Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. 
  • Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. 
  • RR-interval irregularity precedes ventricular fibrillation in ST elevation acute myocardial infarction. 
  • Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. 
  • Racial differences in cardiac catheterization as a function of patients' beliefs. 
  • Racial differences in health-related beliefs, attitudes, and experiences of VA cardiac patients: scale development and application. 
  • Racial variation in the use of coronary-revascularization procedures. 
  • Radial versus femoral access for percutaneous coronary intervention: implications for vascular complications and bleeding. 
  • Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. 
  • Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. 
  • Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. 
  • Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. 
  • Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome. 
  • Reactivity of coronary arteries in relation to serum magnesium levels in patients with ischaemic heart disease--a quantitative coronary angiographic study. 
  • Real-time application of continuous 12-lead ST-segment monitoring: 3 case studies. 
  • Real-time detection and alerting for acute ST-segment elevation myocardial ischemia using an implantable, high-fidelity, intracardiac electrogram monitoring system with long-range telemetry in an ambulatory porcine model. 
  • Real-time three-dimensional echocardiography for measurement of left ventricular volumes. 
  • Real-time three-dimensional echocardiography to construct clinically ready, load-independent indices of myocardial contractile performance. 
  • Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. 
  • Recovery of myocardial function after repetitive episodes of reversible ischemia. 
  • Recurrent ischemia after thrombolysis for acute myocardial infarction. 
  • Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. 
  • Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. 
  • Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. 
  • Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). 
  • Regional geometry and function during myocardial ischemia and recovery. 
  • Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery. 
  • Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. 
  • Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). 
  • Relation of ventricular premature complexes during recovery from a myocardial perfusion exercise stress test to myocardial ischemia. 
  • Relationship Between the Urine Flow Rate and Risk of Contrast-Induced Nephropathy After Emergent Percutaneous Coronary Intervention. 
  • Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. 
  • Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. 
  • Relative importance of electrode placement over number of channels in transient myocardial ischemia detection by Holter monitoring. 
  • Repeat Cell Therapy for Refractory Angina: Déjà vu All Over Again? 
  • Reply: To PMID 22954239. 
  • Report of the third International Society for Holter and Noninvasive Electrocardiology working group on improved electrocardiographic criteria for acute and chronic ischemic heart disease--Lund, Sweden: June 2010. 
  • Response by Capoulade et al to Letter Regarding Article, "Impact of Left Ventricular to Mitral Valve Ring Mismatch on Recurrent Ischemic Mitral Regurgitation After Ring Annuloplasty". 
  • Response to letter regarding article, "surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience". 
  • Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. 
  • Resveratrol regulates autophagy signaling in chronically ischemic myocardium. 
  • Rethinking stable ischemic heart disease: is this the beginning of a new era? 
  • Retinal vessel caliber and microvascular and macrovascular disease in type 2 diabetes: XXI: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. 
  • Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts. 
  • Right ventricular diastolic function in canine models of pressure overload, volume overload, and ischemia. 
  • Right ventricular diastolic relaxation in conscious dog models of pressure overload, volume overload, and ischemia. 
  • Risk of anaphylaxis from aprotinin re-exposure during LVAD removal and heart transplantation. 
  • Role of NADPH oxidase and xanthine oxidase in mediating inducible VT/VF and triggered activity in a canine model of myocardial ischemia. 
  • Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association. 
  • Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. 
  • Roles of collateral arterial flow and ischemic preconditioning in protection of acutely ischemic myocardium. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. 
  • Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. 
  • Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. 
  • Self-regulation in the era of big data: appropriate use of appropriate use criteria. 
  • Sensitive troponin I assay in patients with suspected acute coronary syndrome. 
  • Serial changes of soluble endothelin-1 levels during myocardial ischaemia-reperfusion. Effects of magnesium, diltiazem and a novel MAC-1 inhibitor. 
  • Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. 
  • Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. 
  • Several new considerations in mitral valve repair. 
  • Sex differences in chest pain in patients with documented coronary artery disease and exercise-induced ischemia: Results from the PIMI study. 
  • Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study. 
  • Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease? 
  • Simultaneous comparison of 3 derived 12-lead electrocardiograms with standard electrocardiogram at rest and during percutaneous coronary occlusion. 
  • Single resting hsTnT level predicts abnormal myocardial stress test in acute chest pain patients with normal initial standard troponin. 
  • Single-vessel coronary artery stenosis: myocardial perfusion imaging with Gadomer-17 first-pass MR imaging in a swine model of comparison with gadopentetate dimeglumine. 
  • Small abdominal aortic aneurysms. 
  • Social network diversity and risks of ischemic heart disease and total mortality: findings from the Copenhagen City Heart Study. 
  • Southwestern Internal Medicine Conference: prospects for gene therapy of ischemic heart disease. 
  • Spectrum of ischemic heart disease and the role of biochemical markers. 
  • Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Stem cells for the ischaemic heart. 
  • Stress cardiac magnetic resonance imaging provides effective cardiac risk reclassification in patients with known or suspected stable coronary artery disease. 
  • Stress management and exercise training in cardiac patients with myocardial ischemia. Effects on prognosis and evaluation of mechanisms. 
  • Surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience. 
  • Surgical treatment of moderate ischemic mitral regurgitation. 
  • Surgical treatment of moderate ischemic mitral regurgitation. 
  • Survival after coronary revascularization, with and without mitral valve surgery, in patients with ischemic mitral regurgitation. 
  • Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. 
  • Symptoms of patients with silent ischemia as detected by thallium stress testing. 
  • Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. 
  • Systemic associations of retinal microvascular signs: a review of recent population-based studies. 
  • Technology insight: assessment of myocardial viability by delayed-enhancement magnetic resonance imaging. 
  • Temporal evolution of traditional versus transformed ECG-based indexes in patients with induced myocardial ischemia. 
  • Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience. 
  • Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). 
  • The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. 
  • The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. 
  • The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade. 
  • The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). 
  • The Role for Cardiovascular Remodeling in Cardiovascular Outcomes. 
  • The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. 
  • The Value of Echocardiography in Unexpected Valve Disease in a Patient With Ischemic Cardiomyopathy: Less Is Not Always the Right Answer. 
  • The challenge of defining bleeding among patients with acute coronary syndromes. 
  • The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. 
  • The concordance of intraoperative left ventricular wall-motion abnormalities and electrocardiographic S-T segment changes: association with outcome after coronary revascularization. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. 
  • The direct incorporation of perfusion defect information to define ischemia and infarction in a finite element model of the left ventricle. 
  • The effects of local ventricular pacing on recovery from regional myocardial ischemia. 
  • The impact of autoperfusion on quantitative electrocardiographic parameters of ischemia severity, extent, and "burden" during salvage of elective coronary angioplasty. 
  • The new age of medical genomics. 
  • The new era of clinical research: using data for multiple purposes. 
  • The pathophysiology of acute heart failure--is it all about fluid accumulation? 
  • The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 
  • The relationship between plasma beta-endorphin, opioid receptor activity, and silent myocardial ischemia. 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury. 
  • The role of platelet function testing and genotyping in the stented patient treated with clopidogrel. 
  • The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. 
  • The trouble with ischemia. 
  • The truth and consequences of the COURAGE trial. 
  • The value of estimated functional capacity in estimating outcome: results from the NHBLI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. 
  • The value of exercise thallium imaging. 
  • The value of patient-reported health status in predicting short-term outcomes after coronary artery bypass graft surgery. 
  • The year in cardiovascular surgery. 
  • Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. 
  • Therapy for mental stress-induced myocardial ischemia--reply. 
  • Third universal definition of myocardial infarction. 
  • Time dependence of arrhythmias in ICD patients. 
  • Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. 
  • Tiny solutions for giant cardiac problems. 
  • Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. 
  • Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. 
  • Trends in operator and hospital procedure volume and outcomes for percutaneous transluminal coronary angioplasty, 1996 to 2001. 
  • Triple antithrombotic therapy with prasugrel in the stented patient: concern for more bleeding. 
  • Troponin I degradation in serum of patients with acute ischemic stroke. 
  • Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. 
  • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. 
  • Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. 
  • Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. 
  • Unstable angina--report from a Canadian expert roundtable. 
  • Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. 
  • Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. 
  • Use of coronary angiography and revascularization after acute myocardial infarction. 
  • Use of electrocardiogram indices of myocardial ischemia for risk stratification and decision making of reperfusion strategies. 
  • Usefulness of ischemic response to mental stress in predicting silent myocardial ischemia during ambulatory monitoring. 
  • Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization. 
  • Usefulness of psychosocial treatment of mental stress-induced myocardial ischemia in men. 
  • Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes. 
  • Utility of three-dimensional volume rendering images using electron-beam computed tomography to evaluate possible causes of ischemia from an anomalous origin of the right coronary artery from the left sinus of valsalva. 
  • Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. 
  • Validation of sub-segmental visual scoring for the quantification of ischemic and nonischemic myocardial fibrosis using late gadolinium enhancement MRI. 
  • Valvular disease. 
  • Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy. 
  • Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). 
  • Vorapaxar in the secondary prevention of atherothrombosis. 
  • Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 3: diagnosis and treatment of acute cardiac ischemia: gender issues. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Bennett, Vann, George B. Geller Professor for Research in Molecular Biology in the School of Medicine, Duke Cancer Institute
  • Brennan, J. Matthew, Associate Professor of Medicine, Medicine, Cardiology
  • Hirschey, Matthew, Associate Professor in Medicine, Pharmacology & Cancer Biology
  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Patel, Uptal Dinesh, Adjunct Professor in the Department of Medicine, Medicine, Nephrology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Starmer, Charles Franklin, Professor Emeritus of Computer Science, Computer Science
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Swaminathan, Madhav, Professor of Anesthesiology, Anesthesiology, Cardiothoracic